Table 1.

Demographics and disease characteristics of included patients (n = 198)

	No. with available data	Included patients (n = 198)
Demographics
Sex, female, no. (%)	198	145 (73.2)
Ethnicity, no. (%)
White	161	140 (87.0)
Black	161	16 (9.9)
Asian	161	5 (3.1)
Age, mean ± SD, years	198	51.1 ± 14.3
Diseases characteristics
Autoantibody status a, no. (%)
Anti-nuclear antibody positive	165	156 (94.5)
Anti-centromere	152	43 (28.3)
Anti-topoisomerase	152	85 (55.9)
Anti-RNAP3	152	8 (5.3)
Anti-U1 RNP	152	9 (5.9)
Anti-PM/Scl	152	6 (4.0)
Disease duration, median (IQR), years	198	0.8 (0.4; 1.2)
Duration from RP, median (IQR), years	187	1.3 (0.6; 3.9)
Follow-up, median (IQR), years	198	6.3 (3.8; 8.9)
Skin variables
Cutaneous subset, limited, no. (%)	195	98 (50.3)
mRSS, baseline, median (IQR)	198	8 (2; 18)
Baseline organ involvement, no. (%)
Telangiectasia	183	76 (41.5)
Calcinosis	175	20 (11.4)
Joints	191	114 (59.7)
Muscles	194	53 (27.3)
Digital ulcers	181	76 (42.0)
Gastrointestinal tracts	187	99 (52.9)
Interstitial lung disease	181	72 (39.8)
FVC, median % (IQR)	160	96.0 (76.0; 108.0)
DLCO, median % (IQR)	155	63.0 (50.0; 78.0)
Heart	187	15 (8.0)
Pulmonary hypertension	194	15 (7.7)
Renal crisis	123	12 (9.8)
Biological variable, no. (%)
Baseline CRP level, ≥ 6 mg/L	148	51 (34.5)
Treatments b, no. (%)
Steroids and/or IS	189	127 (68.7)

Numbers are given as % or mean ± standard deviation (SD) or median with interquartile range. Anti-RNAP3 anti-RNA polymerase III antibodies, CRP C-reactive protein; disease duration duration from the first non-RP symptom, DLCO diffusing capacity of the lung for carbon monoxide (% predicted value), FVC forced vital capacity (% predicted value), RP Raynaud’s phenomenon

^aThe sum of % may be different from 100% because some patients had either unidentified ANA or multiple autoantibodies

^bDuring follow-up